Protolichesterinic Acid, Isolated from the Lichen Cetraria islandica, Reduces LRRC8A Expression and Volume-Sensitive Release of Organic Osmolytes in Human Lung Epithelial Cancer Cells

Phytother Res. 2016 Jan;30(1):97-104. doi: 10.1002/ptr.5507. Epub 2015 Nov 9.

Abstract

We have tested the effect of protolichesterinic acid (PA) on the activity of the volume-sensitive release pathway for the organic osmolyte taurine (VSOAC) and the expression of the leucine-rich-repeat-channel 8A (LRRC8A) protein, which constitutes an essential VSOAC component. Exposing human lung cancer cells (A549) to PA (20 µg/mL, 24 h) reduces LRRC8A protein expression by 25% and taurine release following osmotic cell swelling (320 → 200 mOsm) by 60%. C75 (20 µg/mL, 24 h), a γ-lactone with a C8 carbon fatty acid chain, reduces VSOAC activity by 30%, i.e. less than PA. Stearic acid (20 µg/mL, 24 h) has no effect on VSOAC. Hence, length of PA's fatty acid chain adds to γ-lactone's inhibitory action. 5-Lipoxygenase (5-LO) activity is essential for swelling-induced activation of VSOAC. PA has no effect on cellular concentration of leukotrienes (5-HETE/LTB4 ) under hypotonic conditions, excluding that PA mediated inhibition of VSOAC involves 5-LO inhibition. A549 cells exposed to the chemotherapeutic drug cisplatin (10 μM, 24 h) reveal signs of apoptosis, i.e. 25% reduction in cell viability as well as 1.3-, 1.5- and 3.3-fold increase in the expression of LRRC8A, Bax (regulator of apoptosis) and p21 (regulator of cell cycle progression), respectively. PA reduces cell viability by 30% but has no effect on p21/Bax expression. This excludes PA as a pro-apoptotic drug in A549 cells.

Keywords: Bax; C75; arachidonic acid mobilization; cisplatin; p21; taurine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Butyrolactone / analogs & derivatives*
  • 4-Butyrolactone / pharmacology
  • Apoptosis / drug effects
  • Arachidonate 5-Lipoxygenase / metabolism
  • Cell Cycle / drug effects
  • Cell Line, Tumor / drug effects
  • Cell Survival / drug effects
  • Cisplatin / pharmacology
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism
  • Humans
  • Hydroxyeicosatetraenoic Acids / metabolism
  • Lichens / chemistry*
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Membrane Proteins / metabolism*
  • Parmeliaceae / chemistry*
  • Taurine / metabolism*
  • bcl-2-Associated X Protein / metabolism

Substances

  • BAX protein, human
  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Hydroxyeicosatetraenoic Acids
  • LRRC8A protein, human
  • Membrane Proteins
  • bcl-2-Associated X Protein
  • protolichesterinic acid
  • Taurine
  • 5-hydroxy-6,8,11,14-eicosatetraenoic acid
  • Arachidonate 5-Lipoxygenase
  • 4-Butyrolactone
  • Cisplatin